ClinicalTrials.gov posted results on 2026-08-07 for NCT05010629, a phase 2 study of advanced salivary gland cancers that included pembrolizumab in one treatment arm. The trial enrolled 32 participants and reported an objective response rate of 9.4% in evaluable patients.
Background
The posted record covered salivary gland cancer, recurrent salivary gland cancer, metastatic cancer, and adenoid cystic carcinoma. Pembrolizumab, also known as Keytruda, was studied with 9-ING-41 and carboplatin in this trial.
Trial design
This was an active not recruiting study with a brief title of 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma. The record described two parts: Part I with 9-ING-41 plus carboplatin, and Part II with pembrolizumab plus 9-ING-41 plus carboplatin.
Key results
The posted outcomes included a median progression-free survival of 4.3 months in Part I and 7.3 months in Part II. Median overall survival was 15.6 months in Part I, while the Part II overall survival result was listed as NA.
Duration of response in Part II was 6.9 months. Treatment-related adverse events were reported in 16 participants in Part I and 15 participants in Part II. UW-QOL global question 1 mean scores were 51.7 and 48.1 in one posted set of results, and 32.1 and 56.2 in another posted set, with the corresponding standard deviations reported as 38.3, 40.1, 37.4, and 32.
What this means
For clinicians and researchers tracking salivary gland cancer studies, the posted data show modest response activity and provide separate outcome snapshots for the pembrolizumab-containing arm. Because the record does not include primary outcomes, the results should be read as posted trial outcomes rather than a full efficacy conclusion.
Source
This information is based on ClinicalTrials.gov trial results for NCT05010629 posted on 2026-08-07. The record is available at clinicaltrials.gov.